The molecular classification of breast cancer has enabled the identification of subtypes with specific biological, clinical, and prognostic characteristics, including luminal A, associated with a favorable prognosis; luminal B; HER2-positive; and triple-negative, which is linked to a poorer prognosis. Here, ERBB2 is linked to breast carcinoma.